Intercept Pharmaceuticals (FRA:I4P) YoY EBITDA Growth : 99.15% (As of Sep. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Intercept Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Intercept Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Sep. 2023 was 99.15%.

Intercept Pharmaceuticals's EBITDA per Share for the three months ended in Sep. 2023 was €-0.03.

Intercept Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Intercept Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals YoY EBITDA Growth Chart

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

YoY EBITDA Growth

Get a 7-Day Free Trial

23.12

-1.43

34.69

59.59

-91.44

Intercept Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
YoY EBITDA Growth	Get a 7-Day Free Trial															-3,910.96	62.73	19.55	84.03	99.15

Intercept Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Intercept Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2022 is calculated as:

	YoY EBITDA Growth (A: Dec. 2022 )
=	(EBITDA per Share (A: Dec. 2022 )	-	EBITDA per Share (A: Dec. 2021 ))	/	\| EBITDA per Share (A: Dec. 2021 ) \|
=	(-4.338	-	-2.266)	/	\| -2.266 \|
=	-91.44 %

Intercept Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Sep. 2023 is calculated as:

	YoY EBITDA Growth (Q: Sep. 2023 )
=	(EBITDA per Share (Q: Sep. 2023 )	-	EBITDA per Share (Q: Sep. 2022 ))	/	\| EBITDA per Share (Q: Sep. 2022 )) \|
=	(-0.025	-	-2.928)	/	\| -2.928 \|
=	99.15 %

Intercept Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (FRA:I4P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (FRA:I4P) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

305 Madison Avenue, Morristown, NJ, USA, 07960

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Intercept Pharmaceuticals (FRA:I4P) Headlines

No Headlines